山东新华制药股份有限公司（以下简称"公司"）于2025年3月28日召开第十一届董事会第六次 会议，审议通过了《关于会计政策变更的议案》。根据《深圳证券交易所股票上市规则》及《公司 章程》等相关规定，公司本次会计政策变更事项无需提交股东大会审议。本次会计政策变更对公司 财务状况、经营成果和现金流量不会产生影响。现将具体情况公告如下： 一、会计政策变更概述 1.会计政策变更的原因 2024年12月31日，财政部印发《企业会计准则解释第18号》，并自印发之日起实施。具体涉及 浮动收费法下作为基础项目持有的投资性房地产的后续计量以及不属于单项履约义务的保证类质量 保证的会计处理内容的更新。 2.变更前采取的会计政策 本次变更前，公司执行财政部发布的《企业会计准则—基本准则》和各项具体会计准则、企业 会计准则应用指南、企业会计准则解释公告及其他相关规定执行。 证券代码：000756 证券简称：新华制药 公告编号：2025-17 山东新华制药股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 独立审核委员会认为：本次会计政策变更是公司根据 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-11 山东新华制药股份有限公司 第十一届监事会第六次会议决议公告 本公司全体监事保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届监事会第六次会议通知于 2025 年 3 月 14 日以电邮形式发出，会议于 2025 年 3 月 28 日在山东省淄博市高新区鲁泰大道 1 号 公司会议室召开，应到会监事 5 名，实际到会监事 5 名。会议的召开符合有关法律、法规、 规章和公司章程的规定。会议由本公司监事会主席刘承通主持。 会议审议并通过了以下议案： 一、审议通过 2024 年度监事会报告，并将提交 2024 年度周年股东大会审议。 2024 年度监事会报告见同日发布于巨潮资讯网（http://www.cninfo.com.cn）的《山 东新华制药股份有限公司 2024 年年度报告》第十一节。 5 名监事赞成本议案，0 票反对，0 票弃权。 四、审议通过关于 2024 年度计提资产减值损失及处置资产、核销负债的议案，认为董 事会决议程序合法，依据充分。 5 名监事赞成本议案，0 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-10 山东新华制药股份有限公司 第十一届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届董事会第六次会议通知于 2025 年 3 月 14 日以电邮方式发出，会议于 2025 年 3 月 28 日在山东省淄博市高新区鲁泰大道 1 号公司会议室召 开，应到会董事 9 名，实际参会董事 9 名。部分监事会成员和非董事的副总经理列席了会议。会 议由董事长贺同庆主持。会议的召开符合有关法律、法规、规章和公司章程的规定。 会议主要审议并通过了以下议案： 一、审议通过本公司 2024 年度报告及业绩公告，其中 2024 年度报告、2024 年度董事会报告、 2024 年度经审核的财务报告将提交 2024 年度周年股东大会审议； 2024 年度董事会报告见同日发布于巨潮资讯网（http://www.cninfo.com.cn）的《山东新华 制药股份有限公司 2024 年年度报告》第九节。 关联董事张成勇回避表决，参与表决的非关联董事 8 名 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-18 山东新华制药股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 山东新华制药股份有限公司（以下简称"本公司"）于 2025 年 3 月 28 日召开第十一届董事 会第六次会议，审议通过了《关于 2024 年度利润分配的议案》，该事项尚需提交本公司 2024 年 度周年股东大会审议。现将有关事宜公告如下： 一、利润分配方案的基本情况 本公司及其附属公司（"本集团"）2024 年度的财务报告及账目已经致同会计师事务所（特 殊普通合伙）审计，并出具了标准的无保留意见的审计报告。 经致同会计师事务所（特殊普通合伙）审计，本集团 2024 年度实现的归属于上市公司股东的 净利润为人民币 470,023,746.08 元，本公司实现的净利润为人民币 373,661,900.00 元。 2024 年本公司将根据按中国企业会计准则编制的净利润进行分配： 1.按照本公司 2024 年度实现的净利润的 10%提取法定盈余公积金人民币 37,366,190.00 ...

Financial Performance - The company's operating revenue for 2024 reached RMB 8,466,309,803.08, representing a 4.51% increase compared to RMB 8,100,844,707.33 in 2023[13]. - The total profit for 2024 was RMB 533,653,423.32, a slight increase of 0.18% from RMB 532,685,725.02 in the previous year[13]. - Net profit for 2024 decreased by 3.83% to RMB 486,714,573.88, down from RMB 506,107,025.01 in 2023[13]. - The income tax expense for 2024 increased significantly by 76.60% to RMB 46,938,849.44, compared to RMB 26,578,700.01 in 2023[13]. - The basic earnings per share for 2024 was RMB 0.69, a decrease of 6.76% from RMB 0.74 in 2023[13]. - The fully diluted earnings per share for 2024 is projected to be RMB 0.6814[14]. - The company's revenue for the year ended December 31, 2024, was RMB 8,466,310 thousand, an increase of 4.51% compared to 2023[126]. - The net profit attributable to shareholders for the same period was RMB 470,024 thousand, a decrease of 5.33% year-over-year, with basic earnings per share of RMB 0.69[126]. Assets and Liabilities - The company's total assets increased by 8.85% to RMB 9,019,601,567.53 at the end of 2024, compared to RMB 8,286,166,330.90 at the end of 2023[13]. - The net assets attributable to shareholders of the listed company rose by 9.63% to RMB 4,991,588,524.78, up from RMB 4,553,103,869.56 in 2023[13]. - The debt-to-asset ratio stands at 42.15%, calculated as total liabilities divided by total assets multiplied by 100%[182]. - The total capital debt ratio is 33.32%, and the net capital debt ratio is 8.38%, with total debt defined as total borrowings and net debt as total borrowings minus cash and cash equivalents[183]. - The company has sufficient bank credit lines available to meet liquidity needs, with total borrowings amounting to RMB 1,663,214,000 as of December 31, 2024[179]. Shareholder Information - The total number of shareholders increased from 76,496 at the end of 2024 to 78,450 by February 28, 2025[23]. - The total shares outstanding increased from 674.68 million to 682.41 million due to the stock option plan[21]. - The company plans to distribute a year-end dividend of RMB 0.25 per share to all shareholders based on a total share capital of 689,776,535 shares[8]. - The top ten shareholders held a total of 38.63 million restricted shares, accounting for 5.66% of the total share capital[23]. - The company’s basic earnings per share decreased from RMB 0.6971 to RMB 0.6891 after the share changes in 2024[21]. Employee and Management Information - The company has 7,296 employees as of December 31, 2024, with a total salary expenditure of RMB 743,487 million for the year[52]. - The largest group of employees is production personnel, totaling 4,060, followed by sales personnel at 946[53]. - The total shareholding of the vice president, Wei Changsheng, grew from 133,200 shares in 2023 to 242,000 shares in 2024, indicating an increase of about 82%[46]. - The company has maintained no changes in directors, supervisors, or senior management during the reporting period[50]. - Total remuneration for directors, supervisors, and senior management for 2024 is RMB 1,542.10 million[49]. Research and Development - The company obtained 36 drug approvals during the year, including 22 new formulation product approvals and 5 new raw material drug approvals, achieving a historical high[128]. - The company applied for 109 patents and received 57 authorized patents, marking a record achievement[128]. - The company achieved a total of 27 new product production approvals in 2024, including 22 formulation new products and 5 active pharmaceutical ingredients[158]. - The number of R&D personnel decreased by 2.47% to 828, with a notable increase of 32.52% in the number of master's degree holders[160]. Corporate Governance - The board of directors confirmed compliance with the corporate governance code for the year ending December 31, 2024[75]. - The board consists of 4 independent non-executive directors, including one with financial management expertise[77]. - The company has established an independent financial accounting system and management policies[61]. - The company has implemented a performance evaluation and incentive mechanism for senior management, focusing on work performance and adherence to board resolutions[65]. - The company emphasizes the importance of compliance with laws and regulations, ensuring the legality and safety of operations[68]. Market and Sales Performance - Revenue from the pharmaceutical formulation segment increased by 11.91% to RMB 4,072,208,527.22, while the chemical raw materials segment saw a decline of 12.31% to RMB 2,735,954,202.75[146]. - The sales volume of capsules surged by 33.51% to 82,935 thousand units, with production also increasing by 32.01%[149]. - The company is focusing on enhancing its marketing strategies and expanding its international market presence for its formulation products[135]. - The company achieved export revenue of USD 295,916 thousand in 2024, with measures in place to mitigate foreign exchange risk[183]. Internal Controls and Risk Management - The company has established internal controls that effectively cover 100% of the total assets and total revenue in the consolidated financial statements[71]. - The internal control self-assessment report indicates that there are no significant deficiencies in internal controls, achieving the company's internal control objectives[70]. - The company has established a fair pricing mechanism for related party transactions, ensuring no harm to minority shareholders[64]. - The company has implemented a stock option incentive plan, which was first granted on January 15, 2024, following the completion of the plan adopted in 2021[98].

Financial Performance - The total operating revenue for the fiscal year 2024 reached RMB 8,466,309,803.08, representing a 4.51% increase compared to RMB 8,100,844,707.33 in 2023[10] - The net profit attributable to shareholders of the listed company decreased by 5.33% to RMB 470,023,746.08 from RMB 496,512,201.25 in the previous year[10] - The basic earnings per share for 2024 was RMB 0.69, a decrease of 6.76% from RMB 0.74 in 2023[10] - The company proposes a final dividend of RMB 0.25 per share for the year 2024, based on a total issued share count of 689,776,535 shares[19] - The company reported a total comprehensive income of RMB 542,947,084.11, compared to RMB 507,843,039.72 in the previous year, representing an increase of 6.9%[77] - The net profit for the year was RMB 486,714,573.88, a decrease of 3.1% compared to RMB 506,107,025.01 in 2023[77] - The total income tax expense for 2024 reached RMB 46,938,849.44, compared to RMB 26,578,700.01 in 2023, which is an increase of approximately 76.7%[107] - The company reported a total of RMB 187,662,099.63 in dividends for the year 2024, up from RMB 134,936,567.00 in 2023, indicating a growth of about 39.0%[112] Assets and Liabilities - The total assets as of the end of 2024 increased by 8.85% to RMB 9,019,601,567.53 compared to RMB 8,286,166,330.90 at the end of 2023[10] - The total liabilities increased by 8.31% to RMB 3,802,101,150.19 from RMB 3,510,413,044.14 in the previous year[9] - The company's asset-liability ratio stood at 42.15%[41] - The total debt of the company was RMB 1,663,214,000, with cash and cash equivalents amounting to RMB 1,245,023,000[38] - Current assets totaled RMB 3,726,840,162.91 as of December 31, 2024, compared to RMB 3,314,333,616.01 in the previous year, indicating an increase of about 12.48%[72] - The company reported a total inventory of RMB 1,272,856,947.10 as of December 31, 2024, slightly down from RMB 1,312,983,676.75 in 2023, indicating a decrease of about 3.06%[72] Cash Flow - The net cash flow from operating activities improved by 38.58% to RMB 367,610,448.95 from RMB 265,278,895.87 in 2023[10] - Cash and cash equivalents increased by 35.57% to ¥1,245,022,873.47 from ¥918,334,462.29, primarily due to increased bank deposits to meet investment needs[26] - Operating cash inflow increased by 16.06% to ¥8,190,329,183.85 from ¥7,057,191,280.19, driven by enhanced operational efficiency and faster inventory turnover[33] - The net increase in cash and cash equivalents was ¥355,190,755.19, a significant improvement of 255.05% compared to a decrease of ¥229,080,092.64 in the previous year[33] Shareholder Information - The number of registered shareholders as of December 31, 2024, was 76,496, including 39 H-share and 76,457 A-share shareholders[13] - The company issued an additional 7,368,900 A-shares due to the stock option incentive plan during the reporting period[8] - The total number of shares held by major shareholders includes 204,864,092 RMB ordinary shares and 193,314,147 overseas listed foreign shares[16] - The total number of shares held by directors and senior management as of December 31, 2024, is 2,055,050 shares, an increase from 1,215,250 shares in 2023[20] Market and Product Development - The company plans to continue expanding its market presence and invest in new product development to drive future growth[10] - The company achieved sales revenue from new pharmaceutical products, with 22 new formulation product approvals and 5 new raw material drug approvals during the year[45] - The company plans to launch over 50 new products in the next two years, providing strong support for innovation breakthroughs and goal completion by 2025[50] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[85] Operational Efficiency - The company reported a 25.05% decrease in selling expenses, totaling ¥584,739,997.94 compared to ¥780,171,394.31, reflecting cost control measures[30] - The company experienced a 76.60% increase in income tax expenses, amounting to ¥46,938,849.44, attributed to higher profitability in a higher tax rate environment[30] - The company’s liquidity ratios include a current ratio of 133.31% and a quick ratio of 87.78% as of December 31, 2024[37] Research and Development - Research and development expenses were RMB 413,182,811.71, slightly down from RMB 419,239,700.90 in 2023[76] - The goal is to obtain over 15 drug approvals in the year, enhancing the R&D and transformation capabilities of active pharmaceutical ingredients[54] - The company is advancing the development of innovative drugs like OAB-14 and optimizing production processes to enhance competitiveness[55] Strategic Initiatives - The company completed the acquisition of its wholly-owned subsidiary, Ronghua (Zibo) Property Service Co., Ltd.[38] - The company introduced a green channel mechanism for R&D and production transformation, enhancing development vitality and achieving the introduction of 1 Chinese Academy of Engineering academician and 2 national key talent project members[48] - The company’s strategic cooperation with leading enterprises in the commercial sector has deepened, enhancing its market control[46]

一、基本情况 证券代码：000756 证券简称：新华制药 公告编号：2025-09 山东新华制药股份有限公司 关于喷他佐辛注射液取得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的喷他佐辛注射液（以下简称"本品"）《药品注册证书》，批准本品 注册。现将相关情况公告如下： 二、其他相关信息 2023年5月，新华制药向国家药品监督管理局药品审评中心（CDE）递交了喷他佐辛注射 液上市许可申报资料并获受理，2025年3月获得《药品注册证书》，审评结论为：批准注册。 1 剂型：注射剂 规格：1ml:30mg 药品分类：处方药 注册分类：化学药品3类 申请人：山东新华制药股份有限公司 申请事项：境内生产药品注册上市许可 受理号：CYHS2301361 药品批准文号：国药准字H20253528 证书编号：2025S00610 药品名称：喷他佐辛注射液 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发 ...

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the registration of its injection product, Sufentanil Injection, which is indicated for various types of severe chronic pain [1] Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Sufentanil Injection [1] - Sufentanil is a partial agonist of opioid receptors, functioning by inhibiting the central nervous system's conduction system to provide analgesic effects [1] Group 2: Indications and Uses - The product is suitable for various chronic severe pain conditions, including cancer pain, traumatic pain, and postoperative pain [1] - It can also be used as an adjunct medication for anesthesia before surgery or during anesthesia induction [1]

证券代码：000756 证券简称：新华制药 公告编号：2025-08 山东新华制药股份有限公司 关于获得《药品补充申请批准通知书》等相关情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 一、基本情况 药品名称：硫酸氢氯吡格雷片 剂型：片剂 规格：75mg（按C16H16ClNO2S计） 药品分类：处方药 申请人：山东新华制药股份有限公司 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药品监督管理 局核准签发的硫酸氢氯吡格雷片（以下简称"本品"）《药品补充申请批准通知书》，批准本品上市许可 持有人转让补充申请。现将相关情况公告如下： 申请事项：上市许可持有人变更申请 受理号：CYHB2500234 二、其他相关信息 新华制药与北京四环制药有限公司（以下简称"北京四环"）于2024年3月签订了生产技术及持有 人转让合同，合同约定：北京四环将拟取得的硫酸氢氯吡格雷片上市许可持有人及所涉及的技术权属 （生产批件、生产技术的相关知识产权与商业化权益等所有权益，包括但不限于产品生产技术、销售、 市场推广等）一次性全部转让给新华制药，新 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-04 山东新华制药股份有限公司董事会 2025 年 1 月 16 日 山东新华制药股份有限公司 关于部分 A 股股票期权注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东新华制药股份有限公司（以下简称"公司"）于 2024 年 12 月 31 日召开了第十一 届董事会 2024 年第三次临时会议、第十一届监事会 2024 年第三次临时会议，审议通过了 《关于调整 2021 年 A 股股票期权激励计划首次授予行权价格、激励对象名单及授予期权数 量并注销部分期权的议案》，由于公司 2021 年 A 股股票期权激励计划首次授予激励对象中 2 人因岗位调整，1 人因个人原因离职，1 人因达到退休年龄退休，根据公司《2021 年 A 股 股票期权激励计划（草案）》的规定，上述人员已不具备激励对象资格，公司对其已获授但 未行权的 25.74 万份股票期权予以注销。具体内容详见公司于 2025 年 1 月 2 日在巨潮资讯 网（www.cninfo.com.cn）披露的《关于调整 2021 年 ...